These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30036351)

  • 41. The Provenge decision.
    DeVita VT
    Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
    [No Abstract]   [Full Text] [Related]  

  • 42. Lofexidine (Lucemyra) for opioid withdrawal.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):115-117. PubMed ID: 30036346
    [No Abstract]   [Full Text] [Related]  

  • 43. In brief: A new prostate cancer indication for olaparib (Lynparza).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):e106-e107. PubMed ID: 37339094
    [No Abstract]   [Full Text] [Related]  

  • 44. Vaccine approved for prostate cancer. The vaccine, which harnesses the immune system, may provide more treatment options for all cancers.
    Duke Med Health News; 2010 Jul; 16(7):3. PubMed ID: 20662142
    [No Abstract]   [Full Text] [Related]  

  • 45. The regulator disapproves.
    Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
    [No Abstract]   [Full Text] [Related]  

  • 46. Fallout from flip-flops.
    Froese P
    Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
    [No Abstract]   [Full Text] [Related]  

  • 47. FDA approves new combined treatment for advanced prostate cancer.
    Cancer; 2023 Dec; 129(24):3841-3842. PubMed ID: 38102101
    [No Abstract]   [Full Text] [Related]  

  • 48. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2019 Oct; 202(4):661. PubMed ID: 31294666
    [No Abstract]   [Full Text] [Related]  

  • 51. Approval of provenge seen as first step for cancer treatment vaccines.
    Brower V
    J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
    [No Abstract]   [Full Text] [Related]  

  • 52. Ospemifene (Osphena) for dyspareunia.
    Med Lett Drugs Ther; 2013 Jul; 55(1420):55-6. PubMed ID: 23836373
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA approves prostate cancer "vaccine".
    Tanne JH
    BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer.
    Rao Gajula SN; Reddy GN; Reddy DS; Sonti R
    Bioanalysis; 2020 Nov; 12(22):1647-1664. PubMed ID: 33156691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.
    Mitka M
    JAMA; 2012 Jun; 307(24):2576-7. PubMed ID: 22735406
    [No Abstract]   [Full Text] [Related]  

  • 56. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):103-105. PubMed ID: 29913473
    [No Abstract]   [Full Text] [Related]  

  • 58. Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study.
    Sulochana SP; Saini NK; Daram P; Polina SB; Mullangi R
    J Pharm Biomed Anal; 2018 Jul; 156():170-180. PubMed ID: 29709784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
    Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
    N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.